Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References LeqvioⓇ on track for US launch with FDA action date January 1; As with other cardiovascular launches, expect slow initial ramp Launch preparation Enable health system readiness ■ Ensure protocols in place to identify and manage patients in ~200 prioritized systems Drive awareness among HCPs Education: unmet need, importance of LDL-C ■ Leveraging strong CV footprint Facilitate product acquisition ■ Field team helping to navigate access complexities ■ Network of >1000 AICs to support customers new to buy-and-bill Evidence generation V-INITIATE Explore "Leqvio® first" strategy directly after statins1 V-INCEPTION Investigate Leqvio® initiation after recent ACS events1 H1 2022 expectations ■ High interest from early adopters ■ Independent HCPs ready for buy-and-bill ■ AICS - responding to demand ■ Temporary J-code H2 2022 expectations ▪ Permanent J-code available ■Buy-and-bill capabilities established · System P&T committee review complete ■ Finalization of payer coverage policies See appendix for references HCP Healthcare Professional ASCVD Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Cholesterol AIC - Alternative Injection Center P&T Pharmacy & Therapeutics Committee 31 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation